They Want Your Blood: What Longevity Apps Can—and Cannot—Tell You

A growing group of health-tech products is asking consumers for something more intimate than a step count: their blood.

The pitch is appealing. Provide enough biological data, the argument goes, and software can estimate your biological age, identify hidden risks, and suggest ways to live longer. But the promise often runs ahead of what the testing can actually establish. A blood panel may reveal useful information about current health; it does not, by itself, provide a reliable timetable for death or prove that a recommended intervention will extend someone’s life.

That distinction matters as longevity apps turn medical testing into a consumer subscription.

The blood-testing boom behind longevity promises

In an account of testing several health products, The Verge reviewer Victoria Song described giving 24 vials of blood during the year. Half were connected to ordinary medical monitoring, while others were used to build an experimental digital twin or test the longevity app Death Clock.

Death Clock offers a “free” blood panel with its $69 annual subscription. The app uses the results to calculate a biological-age estimate and improve its prediction of when the user will die. In Song’s case, the app estimated death at age 97, on a specific date in 2085.

That level of precision can make a prediction feel scientific. But a date displayed to the day remains an estimate generated by a model, not a medical forecast. The source material does not establish that Death Clock’s prediction has been clinically validated as a reliable way to determine an individual’s lifespan.

Blood testing can measure selected markers associated with health. It cannot remove the uncertainty created by genetics, future illness, accidents, changing treatments, or the limits of the underlying data. A model may calculate a number from available inputs, but the number’s apparent exactness should not be mistaken for certainty.

What the app recommends beyond a blood panel

The blood test is only one part of the commercial ecosystem. Based on the health history uploaded during onboarding, Death Clock also recommended a broad set of tests, devices, screenings, and supplements, including:

• Thyroid, cardiovascular, and liver testing
• A continuous glucose monitor
• A smart scale and blood pressure monitor
• A professional VO2 max assessment
• A liver ultrasound
• Cervical cancer screening
• Daily creatine monohydrate
• An annual full-body skin-cancer examination
• A baseline coronary CT angiography
• APOE testing for Alzheimer’s risk
• A colonoscopy

Some of these may be appropriate in particular circumstances. Whether they make sense depends on factors such as age, symptoms, medical history, family history, previous results, and existing treatment. A software-generated checklist cannot establish that every item is suitable for every user.

The recommendations also span very different categories. A routine screening test, an imaging procedure, genetic risk testing, a wearable device, and a supplement do not carry the same purpose or trade-offs. Presenting them together as steps on a single longevity pathway can blur the difference between:

• Detecting a current medical problem
• Estimating future risk
• Collecting additional data
• Changing behavior
• Selling a product or service

Those distinctions should be clear before a consumer pays for more testing or agrees to an invasive procedure.

More data is not automatically better health care

For someone managing an ongoing condition, regular testing ordered by a clinician may be an established part of care. Consumer testing can also help people track biomarkers and compare results over time, but additional testing can create follow-up appointments, repeat tests, imaging, treatment, anxiety, and expense.

That does not make consumer testing useless. It means the value of a test depends on what decision the result will support. Before ordering a panel, a reader should be able to answer:

1. What is this test designed to detect?
2. What would I do if the result were high, low, or unclear?
3. Who will interpret it?
4. Will the result change my medical care?
5. What follow-up costs or procedures could it lead to?

If there is no sensible answer to the second question, collecting the result may provide less benefit than the marketing suggests.

The difference between biological age and actual age

“Biological age” is an appealing phrase because it implies that a test can reveal how old the body really is. In practice, the term can refer to different kinds of measurements and models. The source material does not specify which biological markers Death Clock uses or how its estimate was validated.

A biological-age score should therefore be treated as a model output, not a settled medical fact. It may summarize selected health information, but it does not replace a diagnosis, a physical examination, or a clinician’s assessment of a person’s complete medical history.

The same caution applies to a predicted lifespan. A result such as “97 years old” can encourage people to think of longevity as a measurable personal target. The number may be more useful as a prompt to review health habits and known risks than as a literal forecast.

The commercial trade-off

The business model is straightforward: health companies receive more data, while users receive reports, scores, recommendations, or access to testing. The consumer may also be directed toward additional tests, devices, or services.

That arrangement raises practical questions even when the product is marketed as a wellness tool:

• What data does the service collect besides laboratory results?
• How long is the data retained?
• Can the user delete it?
• Is it shared with other organizations?
• Are recommendations connected to products the company sells?
• Does the subscription cover interpretation and follow-up, or only the initial test?
• What happens when a result is abnormal?

The material provided does not establish how Death Clock handles every one of these issues. Those are questions a prospective user should investigate in the company’s current terms and privacy documentation before submitting health information.

Blood data can feel more consequential than an ordinary app metric because it is tied to medical history and may reveal information about disease risk. A reader should not assume that a polished dashboard provides the same protections, context, or continuity as care from a medical professional.

How to approach a longevity app responsibly

A longevity app can be used as a supplementary tracking tool, but it should not be treated as an authority on how long someone will live. A cautious approach looks like this:

Start with a specific health question

Testing is more useful when connected to a real question, such as monitoring an existing condition or investigating a symptom. “Find everything that might be wrong with me” is too broad for most consumer services to handle responsibly.

Separate screening from experimentation

A clinically indicated screening test is different from an optional test chosen because an app recommends it. Ask what evidence supports the recommendation and whether it is appropriate for your circumstances.

Review results with a qualified clinician

A single abnormal result may need confirmation. A normal result may not rule out a condition. A clinician can interpret the number alongside symptoms, history, medications, and previous results.

Treat predictions as estimates

A death date or biological-age score is not a guarantee. Avoid making major medical, financial, or personal decisions based solely on a longevity algorithm.

Audit the costs before agreeing

The initial subscription or panel may not represent the total cost. Include follow-up tests, imaging, appointments, devices, supplements, and the time required to interpret the results.

Read the data terms

Find out what happens to laboratory results, health-history information, and derived scores. If the service does not clearly explain retention, sharing, and deletion, that uncertainty is itself relevant to the decision.

The real question is not how much blood can be tested

The longevity market encourages a simple equation: more measurements lead to more knowledge, and more knowledge leads to a longer life. The first step may sometimes be true. The second and third do not automatically follow.

Blood tests can support medical decisions when they are chosen for a clear reason and interpreted in context. They can also feed an impressive-looking dashboard that turns uncertainty into a precise score. The difference lies not only in the laboratory technology, but in the quality of the evidence, the clinical follow-up, and the usefulness of the decision that follows.

Before handing over another vial, consumers should ask what the result will change. If the answer is vague, the promise of a longer life may be doing more work than the test itself.

Sources

• The Verge, “They want your blood,” published October 21, 2026: https://www.theverge.com/column/1015563/blood-death-clock-longevity-apps-health-tech